Related Experiment Videos
Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in
Catherine Mancini1, Michael Van Ameringen, Peter Farvolden
1Anxiety Disorders Clinic, McMaster University Medical Centre, Hamilton Health Sciences Corporation, McMaster Site, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5. mancini@fhs.mcmaster.ca
Journal of Affective Disorders
|March 1, 2002
Summary
For patients with obsessive-compulsive disorder (OCD) and major depressive disorder (MDD), augmenting serotonin reuptake inhibitors (SRIs) with noradrenergic agents can effectively treat persistent depression. This approach offers a potential treatment guideline when initial SRI therapy fails to improve depressive symptoms alongside OCD.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Obsessive-compulsive disorder (OCD) frequently co-occurs with major depressive disorder (MDD).
- Serotonin reuptake inhibitors (SRIs) are a primary treatment for both conditions, typically improving both OCD and depressive symptoms concurrently.
- However, some patients do not experience concurrent symptom improvement with SRI therapy.
Observation:
- This study examined ten patients with OCD and comorbid MDD who experienced worsening depressive symptoms despite adequate SRI treatment.
- These patients were treated with a combination of SRIs and noradrenergic agents.
- Treatment response was assessed using clinician ratings of symptom severity and improvement.
Findings:
- Augmentation therapy led to significant improvement or resolution of major depressive disorder in nine out of ten patients.
- The severity of obsessive-compulsive disorder symptoms showed minimal change after the augmentation treatment.
- This suggests a differential response of depressive symptoms to the combined treatment.
Implications:
- The findings suggest a potential treatment strategy for clinicians managing comorbid MDD in patients with OCD who are unresponsive to initial SRI therapy.
- Augmenting SRIs with noradrenergic agents may be a viable option to address persistent depressive symptoms in this patient population.
- Further research with larger sample sizes and control groups is needed to confirm these findings and establish definitive treatment guidelines.